Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on cancer treatment, announced Thursday that it has received a Complete Response Letter or CRL from the U.S. Food and Drug Administration regarding its New Drug Application or NDA for avasopasem manganese (avasopasem). According to the agency, the given trial data is not sufficient, and that results from an additional clinical trial will be required for resubmission.
from RTT - Before the Bell https://ift.tt/FHfCypY
via IFTTT
No comments:
Post a Comment